SAB Biotherapeutics Inc.

SABS | NASDAQ

Price Alert Chart Builder DCF Calculator

$3.39

-$0.12 (-3.42%)

At close: Sep 21, 2026, 4:00 PM ET

$3.44

+$0.05 (+1.47%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $308.44M

Enterprise Value $210.94M

Beta 0.54

Average Volume 728.82K

Shares Outstanding (Diluted) 79.75M

Shares Change YoY 758.07%

Institutional Ownership N/A

Exchange NASDAQ

ISIN US78397T2024

Price Performance

Price Change 1M -10.6%

Price Change 3M -12.4%

Price Change 6M -11.3%

Price Change YTD -10.1%

Price Change 1Y 36.7%

Price Change 3Y -38.0%

Price Change 5Y -96.6%

1M CAGR (ann.) -13.1%

1Y CAGR (ann.) 21.5%

5Y CAGR (ann.) -49.2%

All-Time CAGR -45.4%

Valuation

PE Ratio -3.94

Forward PE N/A

PEG Ratio 0.00

Forward PEG -0.03

PS Ratio N/A

Forward PS 6,168.90

PB Ratio 1.44

P/FCF Ratio -4.24

P/Adj. FCF Ratio -3.28

P/OCF Ratio -3.94

EV/Sales N/A

EV/EBIT -16.82

EV/EBITDA -22.29

EV/FCF -2.90

Earnings Yield -25.4%

FCF Yield -23.6%

Adj. FCF Yield -30.5%

Financial Health

Net Cash $97.5M

Total Debt $5.13M

Cash & Short-Term Investments $102.63M

Total Assets $238.21M

Current Ratio 9.22

Quick Ratio 9.22

Debt / Equity Ratio 0.02

Debt / EBITDA -0.54

Debt / FCF -0.07

OCF / Debt -13.29

Interest Coverage -310.26

Altman Z-Score 7.32

Piotroski F-Score 2

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -29.3%

Returns

Return on Assets -5.4%

Return on Equity -6.7%

Return on Invested Capital -31.6%

Return on Capital Employed -31.7%

Return on Tangible Assets -5.4%

Historical Growth (CAGR)

Revenue CAGR 3Y -144.1%

Revenue CAGR 5Y -88.4%

Revenue CAGR 10Y N/A

EPS CAGR 3Y 72.1%

EPS CAGR 5Y 23.6%

EPS CAGR 10Y N/A

FCF CAGR 3Y -37.3%

FCF CAGR 5Y -32.5%

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 8

EPS Growth Next 3Y -37.7%

Revenue Growth Next 3Y N/A

Earnings Date Nov 12, 2026

EPS Estimate (next Q) -$0.27

EPS Growth Est (next Q) 28.6%

Revenue Est (next Q) $125K

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $11.33

Price Target Upside 234.2%

Cash Flow

Operating Cash Flow $-68.21M

Free Cash Flow $-72.7M

Adj. Free Cash Flow $-94.03M

FCF Per Share -$0.91

OCF Per Share -$0.86

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $-2.28M

Operating Income $-71.82M

EBITDA $-9.46M

Net Income $-12.78M

EPS (Diluted) -$0.86

Revenue / Employee N/A

Profit / Employee $-148.55K

Employees 86